Research Reports | Market Assessment
November 2015

Neuropathic Pain | Pharmacor | G7 | 2015

In 2014, total sales for neuropathic pain (NP) in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) were estimated to be approximately $7.2 billion. Current treatment of NP involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. The current and forthcoming generic availability of early-line analgesics across several drug classes, as well as the entrenchment of available treatment options in current medical practice, present notable barriers to market penetration of new drugs. Nevertheless, commercial opportunity exists for drug developers that can address key areas of unmet need, the most significant of which are for more-effective and/or safer and better-tolerated analgesics.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports